Enhanced cytotoxicity to cancer cells by mitochondria-targeting MWCNTs containing platinum(IV) prodrug of cisplatin

Biomaterials

Volumn 35, Issue 2, 2014, Pages 748-759

  Yoong, Sia Lee ^a   Wong, Bin Sheng ^b   Zhou, Qi Ling ^b   Chin, Chee Fei ^b   Li, Jian ^b   Venkatesan, Thirumalai ^b   Ho, Han Kiat ^b   Yu, Victor ^a,b   Ang, Wee Han ^b   Pastorin, Giorgia ^a,b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

3 Bromopyruvate; Cisplatin; Mitochondria; Multi walled carbon nanotubes; Platinum(IV) prodrug; Rhodamine

Indexed keywords

3-BROMOPYRUVATE; BIOACTIVE MOLECULES; CIS-PLATIN; FUNCTIONALIZATIONS; PRODRUGS; RHODAMINE; STRUCTURAL SIMILARITY; TARGETING CAPABILITY;

ASPECT RATIO; CELL CULTURE; CELL MEMBRANES; MULTIWALLED CARBON NANOTUBES (MWCN); PLATINUM; PLATINUM COMPOUNDS;

MITOCHONDRIA;

CISPLATIN; FLUORESCEIN; MULTI WALLED NANOTUBE; NANOCONJUGATE; PRODRUG; RHODAMINE 110;

ARTICLE; CANCER CELL; CELL VIABILITY; CONJUGATE; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG POTENCY; DRUG TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; NANOENCAPSULATION; PRIORITY JOURNAL;

3-BROMOPYRUVATE; CISPLATIN; MITOCHONDRIA; MULTI-WALLED CARBON NANOTUBES; PLATINUM(IV) PRODRUG; RHODAMINE;

ANTINEOPLASTIC AGENTS; CELL SURVIVAL; CISPLATIN; DRUG DELIVERY SYSTEMS; DRUG SYNERGISM; FLOW CYTOMETRY; HUMANS; MCF-7 CELLS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICROSCOPY, CONFOCAL; MICROSCOPY, ELECTRON, TRANSMISSION; MITOCHONDRIA; NANOTUBES, CARBON; PLATINUM; PRODRUGS; PYRUVATES; RHODAMINES;

EID: 84886753316     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.09.036     Document Type: Article

References (54)

1. Fulda S., Galluzzi L., Kroemer G. Targeting mitochondria for cancer therapy. Nat Rev Drug Discov 2010, 9:447-464.
2. Armstrong J.S. Mitochondrial medicine: pharmacological targeting of mitochondria in disease. Br J Pharmacol 2007, 151:1154-1165.
3. Adams J.M., Cory S. The bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007, 26:1324-1337.
4. Malhi S.S., Murthy R.S. Delivery to mitochondria: a narrower approach for broader therapeutics. Expert Opin Drug Deliv 2012, 9:909-935.
5. Smith R.A.J., Murphy M.P. Animal and human studies with the mitochondria-targeted antioxidant MitoQ. Ann N Y Acad Sci 2010, 1201:96-103.
6. Gruber J., Fong S., Chen C.-B., Yoong S., Pastorin G., Schaffer S., et al. Mitochondria-targeted antioxidants and metabolic modulators as pharmacological interventions to slow ageing. Biotechnol Adv 2013, 31:563-592.
7. Snow B.J., Rolfe F.L., Lockhart M.M., Frampton C.M., O'Sullivan J.D., Fung V., et al. Adouble-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson's disease. Mov Disord 2010, 25:1670-1674.
8. Gane E.J., Weilert F., Orr D.W., Keogh G.F., Gibson M., Lockhart M.M., et al. The mitochondria-targeted anti-oxidant mitoquinone decreases liver damage in a phase II study of hepatitis C patients. Liver Int 2010, 30:1019-1026.
9. Kelso G.F., Porteous C.M., Coulter C.V., Hughes G., Porteous W.K., Ledgerwood E.C., et al. Selective targeting of a redox-active ubiquinone to mitochondria within cells: antioxidant and antiapoptotic properties. JBiol Chem 2001, 276:4588-4596.
10. Kang B.H., Plescia J., Song H.Y., Meli M., Colombo G., Beebe K., et al. Combinatorial drug design targeting multiple cancer signaling networks controlled by mitochondrial Hsp90. JClin Invest 2009, 119:454-464.
11. Kang B.H., Siegelin M.D., Plescia J., Raskett C.M., Garlick D.S., Dohi T., et al. Preclinical characterization of mitochondria-targeted small molecule hsp90 inhibitors, gamitrinibs, in advanced prostate cancer. Clin Cancer Res 2010, 16:4779-4788.
12. Brouty-Boye D., Kolonias D., Wu C.J., Savaraj N., Lampidis T.J. Relationship of multidrug resistance to rhodamine-123 selectivity between carcinoma and normal epithelial cells: taxol and vinblastine modulate drug efflux. Cancer Res 1995, 55:1633-1638.
13. Peer D., Karp J.M., Hong S., Farokhzad O.C., Margalit R., Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007, 2:751-760.
14. Goren D., Horowitz A.T., Tzemach D., Tarshish M., Zalipsky S., Gabizon A. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump. Clin Cancer Res 2000, 6:1949-1957.
15. Lee E.S., Na K., Bae Y.H. Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumor. JControl Release 2005, 103:405-418.
16. Marrache S., Dhar S. Engineering of blended nanoparticle platform for delivery of mitochondria-acting therapeutics. Proc Natl Acad Sci U S A 2012, 109:16288-16293.
17. Pastorin G. Crucial functionalizations of carbon nanotubes for improved drug delivery: a valuable option?. Pharm Res 2009, 26:746-769.
18. Lacerda L., Russier J., Pastorin G., Herrero M.A., Venturelli E., Dumortier H., et al. Translocation mechanisms of chemically functionalised carbon nanotubes across plasma membranes. Biomaterials 2012, 33:3334-3343.
19. Kostarelos K., Lacerda L., Pastorin G., Wu W., Wieckowski S., Luangsivilay J., et al. Cellular uptake of functionalized carbon nanotubes is independent of functional group and cell type. Nat Nanotechnol 2007, 2:108-113.
20. Vashist S.K., Zheng D., Pastorin G., Al-Rubeaan K., Luong J.H.T., Sheu F.-S. Delivery of drugs and biomolecules using carbon nanotubes. Carbon 2011, 49:4077-4097.
21. Janib S.M., Moses A.S., MacKay J.A. Imaging and drug delivery using theranostic nanoparticles. Adv Drug Deliv Rev 2010, 62:1052-1063.
22. Zhou F., Xing D., Wu B., Wu S., Ou Z., Chen W.R. New insights of transmembranal mechanism and subcellular localization of noncovalently modified single-walled carbon nanotubes. Nano Lett 2010, 10:1677-1681.
23. Zhou F., Wu S., Wu B., Chen W.R., Xing D. Mitochondria-targeting single-walled carbon nanotubes for cancer photothermal therapy. Small 2011, 7:2727-2735.
24. Zhou F., Wu S., Yuan Y., Chen W.R., Xing D. Mitochondria-targeting photoacoustic therapy using single-walled carbon nanotubes. Small 2012, 8:1543-1550.
25. Wang D., Lippard S.J. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 2005, 4:307-320.
26. Dhar S., Liu Z., Thomale J., Dai H., Lippard S.J. Targeted single-wall carbon nanotube-mediated Pt(IV) prodrug delivery using folate as a homing device. JAm Chem Soc 2008, 130:11467-11476.
27. Bhirde A.A., Patel V., Gavard J., Zhang G., Sousa A.A., Masedunskas A., et al. Targeted killing of cancer cells invivo and invitro with EGF-directed carbon nanotube-based drug delivery. ACS Nano 2009, 3:307-316.
28. Hampel S., Kunze D., Haase D., Kramer K., Rauschenbach M., Ritschel M., et al. Carbon nanotubes filled with a chemotherapeutic agent: a nanocarrier mediates inhibition of tumor cell growth. Nanomedicine (Lond) 2008, 3:175-182.
29. Li J., Yap S.Q., Yoong S.L., Nayak T.R., Chandra G.W., Ang W.H., et al. Carbon nanotube bottles for incorporation, release and enhanced cytotoxic effect of cisplatin. Carbon 2012, 50:1625-1634.
30. Raoof M., Cisneros B.T., Guven A., Phounsavath S., Corr S.J., Wilson L.J., et al. Remotely triggered cisplatin release from carbon nanocapsules by radiofrequency fields. Biomaterials 2013, 34:1862-1869.
31. Li J., Yap S.Q., Chin C.F., Tian Q., Yoong S.L., Pastorin G., et al. Platinum(iv) prodrugs entrapped within multiwalled carbon nanotubes: selective release by chemical reduction and hydrophobicity reversal. Chem Sci 2012, 3:2083-2087.
32. Niazi A.K., Mileshina D., Cosset A., Val R., Weber-Lotfi F., Dietrich A. Targeting nucleic acids into mitochondria: progress and prospects. Mitochondrion 2013, 13:548-558.
33. Kazak L., Reyes A., Holt I.J. Minimizing the damage: repair pathways keep mitochondrial DNA intact. Nat Rev Mol Cell Biol 2012, 13:659-671.
34. Rakhi R.B., Sethupathi K., Ramaprabhu S. Synthesis and hydrogen storage properties of carbon nanotubes. Int J Hydrog Energy 2008, 33:381-386.
35. Coin I., Beyermann M., Bienert M. Monitoring solid phase peptide synthesis. Protoc Exch 2007, Available from:. http://www.nature.com/protocolexchange/protocols/366, 10.1038/nprot.2007.461.
36. Yudasaka M., Ajima K., Suenaga K., Ichihashi T., Hashimoto A., Iijima S. Nano-extraction and nano-condensation for C60 incorporation into single-wall carbon nanotubes in liquid phases. Chem Phys Lett 2003, 380:42-46.
37. Wörle-Knirsch J.M., Pulskamp K., Krug H.F. Oops they did it again! Carbon nanotubes hoax scientists in viability assays. Nano Lett 2006, 6:1261-1268.
38. Wu W., Li R., Bian X., Zhu Z., Ding D., Li X., et al. Covalently combining carbon nanotubes with anticancer agent: preparation and antitumor activity. ACS Nano 2009, 3:2740-2750.
39. Huang W., Fernando S., Allard L.F., Sun Y.-P. Solubilization of single-walled carbon nanotubes with diamine-terminated oligomeric poly(ethylene glycol) in different functionalization reactions. Nano Lett 2003, 3:565-568.
40. Jeannot V., Salmon J.M., Deumie M., Viallet P. Intracellular accumulation of rhodamine 110 in single living cells. JHistochem Cytochem 1997, 45:403-412.
41. Cullen KJ., Yang Z., Schumaker L., Guo Z. Mitochondria as a critical target of the chemotheraputic agent cisplatin in head and neck cancer. JBioenerg Biomembr 2007, 39:43-50.
42. Salvioli S., Ardizzoni A., Franceschi C., Cossarizza A. JC-1, but not DiOC6(3) or rhodamine 123, is a reliable fluorescent probe to assess δΨ changes in intact cells: implications for studies on mitochondrial functionality during apoptosis. FEBS Lett 1997, 411:77-82.
43. Ihrlund L.S., Hernlund E., Khan O., Shoshan M.C. 3-Bromopyruvate as inhibitor of tumour cell energy metabolism and chemopotentiator of platinum drugs. Mol Oncol 2008, 2:94-101.
44. Ganapathy-Kanniappan S., Vali M., Kunjithapatham R., Buijs M., Syed L.H., Rao P.P., et al. 3-bromopyruvate: a new targeted antiglycolytic agent and a promise for cancer therapy. Curr Pharm Biotechnol 2010, 11:510-517.
45. Chen L.B. Mitochondrial membrane potential in living cells. Annu Rev Cell Biol 1988, 4:155-181.
46. Johnson L.V., Walsh M.L., Chen L.B. Localization of mitochondria in living cells with rhodamine 123. Proc Natl Acad Sci U S A 1980, 77:990-994.
47. Usrey M.L., Nair N., Agnew D.E., Pina C.F., Strano M.S. Controlling the electrophoretic mobility of single-walled carbon nanotubes: a comparison of theory and experiment. Langmuir 2007, 23:7768-7776.
48. Mesgari S., Poon Y.F., Yan L.Y., Chen Y., Loo L.S., Thong Y.X., et al. High selectivity cum yield gel electrophoresis separation of single-walled carbon nanotubes using a chemically selective polymer dispersant. JPhys Chem C 2012, 116:10266-10273.
49. Ma X., Zhang L.H., Wang L.R., Xue X., Sun J.H., Wu Y., et al. Single-walled carbon nanotubes alter cytochrome c electron transfer and modulate mitochondrial function. ACS Nano 2012, 6:10486-10496.
50. Li R., Wu R., Wu M., Zou H., Ma H., Yang L., et al. MEKC-LIF analysis of rhodamine123 delivered by carbon nanotubes in K562 cells. Electrophoresis 2009, 30:1906-1912.
51. Battigelli A., Russier J., Venturelli E., Fabbro C., Petronilli V., Bernardi P., et al. Peptide-based carbon nanotubes for mitochondrial targeting. Nanoscale 2013, 5:9110-9117.
52. Holt B.D., Dahl K.N., Islam M.F. Cells take up and recover from protein-stabilized single-wall carbon nanotubes with two distinct rates. ACS Nano 2012, 6:3481-3490.
53. Nadakavukaren K.K., Nadakavukaren J.J., Chen L.B. Increased rhodamine 123 uptake by carcinoma cells. Cancer Res 1985, 45:6093-6099.
54. Bernal S.D., Lampidis T.J., Summerhayes I.C., Chen L.B. Rhodamine-123 selectively reduces clonal growth of carcinoma cells invitro. Science 1982, 218:1117-1119.